Navigation Links
Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
Date:5/17/2011

sly used other oral ED therapies. Each of these trials has a similar trial design with patients undergoing a four-week, non-treatment run-in period followed by 12 weeks of treatment. Primary endpoints of the studies are improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the EF domain score of the International Index of Erectile Function (IIEF). In both the TA-301 and TA-302 studies, all doses of avanafil met the primary endpoints, with successful intercourse achieved by some subjects in 15 minutes or less after administration. TA-314 was an open label, long-term safety and efficacy study required as part of the NDA.  In TA-314, patients also had significant improvement in erectile function as measured by SEP2, SEP3 and IIEF. 

VIVUS has also held a pre-NDA meeting with the FDA to confirm that the pre-clinical and clinical requirements necessary for the filing of an NDA have been met. In total, the phase 3 avanafil clinical program enrolled approximately 1,350 subjects. VIVUS expects to file the NDA for avanafil in the second quarter of 2011.

About Erectile Dysfunction (ED)Erectile Dysfunction (ED) is defined as the inability to attain and maintain an erection sufficient for sexual intercourse. According to the Massachusetts Male Aging Study (MMAS), ED affects an estimated 52 percent of men between the ages of 40 and 70. The prevalence of ED increases with age and can be affected by a variety of factors, including certain medications such as anti-hypertensives and histamine receptor antagonists; lifestyle, such as tobacco or alcohol use; diseases, including diabetes and cardiovascular conditions; and spinal cord injuries. Studies have shown that up to 58% of men with diabetes have erectile dysfunction.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigat
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. today announced ... Melbourne, Australia of MSP-2017, ... treatment of paroxysmal supraventricular tachycardia (PSVT).  The results ... well tolerated at single doses up to and ... desirable PK properties including rapid onset, and validating ...
(Date:11/24/2014)... Nov. 24, 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced today that Sergio Traversa ... the LD MICRO "MAIN Event" Micro-Cap Growth Conference on ... at the Luxe Sunset Bel Air Hotel, which is ... Angeles, California . The presentation is ...
(Date:11/24/2014)... Theater, LLC, announced today that their technology will be ... Europe,s first simulation center, The ... Planner (SRP) and the Surgical Navigation Advanced Platform (SNAP) ... navigation and augmented reality capabilities in the operating room ... Department of Neurosurgery at Mount Sinai Health System in ...
Breaking Medicine Technology:Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3Relmada Therapeutics To Present At LD MICRO Conference 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... Healthcare and,Laboratory Corporation of America(R) Holdings (LabCorp(R)) ... agreement to discuss future,possibilities to co-develop new ... diagnostics, metabolic syndrome, oncology and diabetes. Under ... new tests that,could make the biggest impact ...
... of the American Pain Society ... ... sustained pain relief from diabetic neuropathic pain (DNP),compared to placebo-treated patients, according ... (APS) in Tampa, Fla., "This is the first placebo-controlled trial of ...
Cached Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
(Date:11/23/2014)... (PRWEB) November 24, 2014 Tbdress.com ... be available online on Nov. 28, 2014. The special offer ... , Tbdress.com is one of the world’s largest women’s ... styles and colors. People can enjoy great discounts on that ... can enjoy free delivery (for orders above $89). , People ...
(Date:11/23/2014)... -- The holidays can be a challenge for families ... major meltdowns, an expert says. "Holidays with family ... when you have children with special needs, some care ... at University of the Sciences in Philadelphia, said in ... your hosts or visitors know what special requirements are ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
Breaking Medicine News(10 mins):Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
... on cells could prompt overeating, study suggests , THURSDAY, ... more evidence that dopamine -- a brain chemical associated ... role in obesity. , Researchers at the U.S. government,s ... obese rats have lower levels of dopamine D2 receptors ...
... Loss Narrows on Growth of Services Revenues, Higher Margins ... Outlook Improves for 2007 Net Results, POWAY, Calif., ... leading provider of medical diagnostic imaging systems,and services to ... for the third quarter and nine months ended,September 30, ...
... The 5th site in the,AZoNetwork portfolio builds on ... AZoNano.com - the A to Z of Nanotechnology and ... ( http://www.AZoOptics.com ) is the latest AZoNetwork,online knowledge base ... science, design and engineering community with a,continuously updating resource ...
... issued,today by the law firm of Schiffrin Barroway Topaz & ... action lawsuit was filed in the,United States District Court for ... of Aetna Inc. (NYSE: AET ) ("Aetna" or,the "Company") ... Period"). If you wish to discuss this action or ...
... steps to help members get the care they need, ... AET ) is making it,easier for members impacted by ... access employee assistance and,behavior health programs. In addition, the ... help them access care in San Diego,County, where many ...
... Mayo Clinic study due to be presented at the ... in San Diego this week shows that a chromosome ... identifying chromosomal genetic abnormalities associated with plasma cell malignancies. ... a patients prognosis and likelihood to respond to a ...
Cached Medicine News:Health News:Brain's 'Reward Chemical' May Help Spur Obesity 2Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 2Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 3Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 4Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 5Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 6Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 7Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 8Health News:Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results 9Health News:AZoOptics.com - The A to Z of Optics Launched By AZoNetwork 2Health News:Shareholder Class Action Filed Against Aetna Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Aetna Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Aetna Reminds Members Affected by California Wildfires Where to Call for Help 2Health News:Aetna Reminds Members Affected by California Wildfires Where to Call for Help 3Health News:Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study 2
Sponge style scrub brush and nail cleaner is impregnated for antimicrobial cleaning....
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Biosoft plus Neu Thera ... anti-infective alcohol hand sanitizer ... ingredients of the Neu-Thera ... been clinically proven to ...
... The use of waterless alcohol hand sanitizers ... are replacing soap and water as the ... per the 2002 CDC Draft Guidelines for ... of healthcare associated infections can be prevented ...
Medicine Products: